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Editorial
The International Society for Biological Therapy of Cancer
(iSBTc) and BioMed Central are proud and delighted to
announce their collaboration in editing a section of the
Journal of Translational Medicine devoted to promoting the
field of Tumor Immunology and Biological Cancer Ther-
apy.
Addressing a need for a dedicated forum on 
cancer immunology and immunotherapy
We are convinced that we are living in exciting times for
this emerging field. Major and multiple discoveries in
immunology have been expanding the frontiers of our
understanding of immunity at an ever increasing pace.
These discoveries include a long list of cytokines, the elu-
cidation of the structural basis of antigen recognition by
the cells of the adaptive immune system - the B and T lym-
phocytes -, the identification of dendritic cells, the dissec-
tion of the mechanisms of thymic selection of the mature
T cell repertoire, the outlining of T and B cell differentia-
tion pathways, the mapping of crucial checkpoints along
the pathways of adaptive immune responses, the conclu-
sive demonstration of immunosurveillance against
tumors, and the molecular links between innate and
adaptive immune response mechanisms. In parallel, the
translation of major insights made in animal models to
the clinics has also picked up momentum. Translational
research has gained a respectable place among academic,
industry and government institutions alike. Recent years
have brought a busy and exciting dialog between the
bench, the bedside and back to the bench. A large number
of novel therapies based on the immunobiology of
tumors have been or are currently being tested in the clin-
ics. As well, sophisticated preclinical models of major
tumor types are generated at an astonishing speed to
address major questions of basic and applied cancer
research. The community as a whole is now oriented
toward the prospect of identifying combination anti-can-
cer therapies that may reach unmatched clinical efficacy.
Such levels of activity require appropriate vehicles and
means to share new knowledge and to catalyze the devel-
opment of the field.
The boundless possibilities offered by a rapidly pub-
lished, open-access, online communication of results and
exchange of opinions are potent tools to most efficiently
achieve these tasks. Thus, this section of the Journal of
Translational Medicine provides a venue for publication of
original research articles, literature reviews, opinion/posi-
tion papers and a forum to discuss the hot issues in Tumor
Immunology and Biological Cancer Therapy research. On
behalf of the International Society for Biological Therapy
of Cancer, we would like to invite you to submit your
work, your thoughts and/or to engage in informal discus-
sions. We welcome you and look forward to your contri-
butions.
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"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
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